ZIM Laboratories Limited (BOM:541400)
114.60
+5.00 (4.56%)
At close: Aug 17, 2026
ZIM Laboratories Revenue
ZIM Laboratories had revenue of 941.79M INR in the quarter ending June 30, 2026, with 31.25% growth. This brings the company's revenue in the last twelve months to 3.97B, up 7.52% year-over-year. In the fiscal year ending March 31, 2026, ZIM Laboratories had annual revenue of 3.74B, down -1.22%.
Revenue (ttm)
3.97B
Revenue Growth
+7.52%
P/S Ratio
1.55
Revenue / Employee
6.28M
Employees
632
Market Cap
6.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.74B | -46.31M | -1.22% |
| Mar 31, 2025 | 3.79B | 115.14M | 3.13% |
| Mar 31, 2024 | 3.68B | -310.92M | -7.80% |
| Mar 31, 2023 | 3.99B | 651.00M | 19.52% |
| Mar 31, 2022 | 3.34B | 261.64M | 8.51% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Kopran | 7.00B |
| Wanbury | 6.53B |
| Hexagon Nutrition | 4.15B |
| Albert David | 3.64B |
| Bharat Parenterals | 3.23B |
| Amanta Healthcare | 2.91B |
ZIM Laboratories News
- 9 months ago - Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules - Business Upturn
- 1 year ago - ZIM Laboratories secures marketing authorization in Australia for urology drug combination - Business Upturn
- 1 year ago - ZIM Laboratories shares in focus as company gets first marketing approval in Australia - Business Upturn